10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-A multicenter phase-II trial (CISTAXOL)

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 83-89

  Eberhardt, Wilfried Ernst Erich ^a   Gauler, Thomas Christoph ^a   LePechoux, Cecile ^b   Stamatis, Georgios ^c   Bildat, Stephan ^d   Krbek, Thomas ^e   Welter, Stefan ^c   Grunenwald, Dominique ^f   Fischer, Berthold ^g   Rodrigo, Hepp de los Rios ^h   Theegarten, Dirk ^a   Le Chevalier, Thierry ^b   Seeber, Siegfried ⁱ   Stuschke, Martin ^a   Poettgen, Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Ruhrlandclinic ^*  (Germany)

^d Klinikum Herford   (Germany)

^e Krankenhaus Bethanien   (Germany)

^f HÔPITAL TENON   (France)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h EVANGELISCHES KRANKENHAUS   (Germany)

ⁱ KLINIKEN ESSEN MITTE   (Germany)

Author keywords

10 Year survival; Induction chemoradiotherapy; Lung cancer; Prognostic factors; Surgery; Trimodality treatment

Indexed keywords

CISPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; EMBOLISM; ESOPHAGITIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LARGE CELL CARCINOMA; LEUKOPENIA; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISCELLANEOUS INFECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SKULL IRRADIATION; STOMATITIS; THROMBOCYTOPENIA;

10-YEAR SURVIVAL; INDUCTION CHEMORADIOTHERAPY; LUNG CANCER; PROGNOSTIC FACTORS; SURGERY; TRIMODALITY TREATMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVORS; TREATMENT OUTCOME;

EID: 84884411186     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.007     Document Type: Article

References (40)

1. Malvezzi M., Bertuccio P., Levi F.C., La Vecchia C., Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2012, 23(4):1044-1052.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
3. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 Aug, 2(8):706-714.
4. Vansteenkiste J.F., Mortelmans L.A. FDG-PET in the locoregional lymph node staging of non-small cell lung cancer. A comprehensive review of the leuven lung cancer group experience. Clin Positron Imaging 1999 Jul, 2(4):223-231.
5. Herth F.J. Nonsurgical staging of the mediastinum: EBUS and EUS. Semin Respir Crit Care Med 2011, 32((1) February):62-68.
6. Farray D., Mirkovic N., Albain K.S. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005, 23(14):3257-3269.
7. Albain K.S., Swann R.S., Rusch V.W., Turrisi A.T., Shepherd F.A., Smith C., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374(9687):379-386.
8. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998, 16(2):622-663.
9. Friedel G., Budach W., Dippon J., Spengler W., Eschmann S.M., Pfannenberg C., et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010, 28(6):942-948.
10. Thomas M., Rübe C., Hoffknecht P., Macha H.N., Freitag L., Linder A., et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008, 9:636-648. for the German Lung Cancer Cooperative Group.
11. Edelman M.J., Suntharalingam M., Burrows W., Kwong K.F., Mitra N., Gamliel Z., et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 2008, 86((3) September):903-910.
12. Choi N.C., Carey R.W., Daly W., Mathisen D., Wain J., Wright C., et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997, 15:712-722.
13. Albain K.S., Rush V.W., Crowley J.J., Rice T.W., Turrisi A.T., Weick J.K., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA(N2) and IIIB non-small-cell lung cancer: Mature results of South West Oncology Group phase-II study 8805. J Clin Oncol 1995, 13:1880-1892.
14. DeCamp M.M., Rice T.W., Adelstein D.J., Chidel M.A., Rybicki L.A., Murthy S.C., et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg 2003, 126:17-27.
15. Grunenwald D.H., Andre F., Le P.C., Le Péchoux C., Girard P., Lamer C., et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small-cell lung cancer. J Thorac Cardiovasc Surg 2001, 122:796-802.
16. Weder W., Collaud S., Eberhardt W.E., Hillinger S., Welter S., Stahel R., et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010, 139((6) June):1424-1430.
17. Lorent N., De Leyn P., Lievens Y., Verbeken E., Nackaerts K., Dooms C., et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004, 15(11):1645-1653.
18. Stupp R., Mayer M., Kann R., Weder W., Zouhair A., Betticher D.C., et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol 2009 Aug, 10(8):785-793.
19. Pöttgen C., Eberhardt W.E., Gauler T., Krbek T., Berkovic K., Jawad J.A., et al. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. Int J Radiat Oncol Biol Phys 2010, 76(3):809-815.
20. Pöttgen C., Eberhardt W., Bildat S., Stüben G., Stamatis G., Hillejan L., et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol 2002, 13((3) March):403-411.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958, 53:457-481.
22. R Develompent Core Team R: A language and environment for statistical computing 2012, R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0, http://www.R-project.org/.
23. Scrucca L., Santucci A., Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl 2007, 40(4):381-387.
24. Stamatis G., Eberhardt W., Stueben G., Bildat S., Dahler O., Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999, 68:1144-1149.
25. Stamatis G., Djuric D., Eberhardt W., Pöttgen C., Zaboura G., Fechner S., et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients. Eur J Cardiothorac Surg 2002, 22((2) August):292-297.
26. Eberhardt W.E., Stamatis G., Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet 2009, 374(9687):359-360.
27. van Meerbeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007, 99(6):442-450.
28. Betticher D.C., Hsu Schmitz S.F., Tötsch M., Hansen E., Joss C., von Briel C., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003, 21(9):1752-1759.
29. Rendina E.A., Venuta F., De Giacomo T., Ciccone A.M., Ruvolo G., Coloni G.F., Ricci C. Induction chemotherapy for centrally located non-small cell lung cancer. J Thorac Cardiovasc Surg 1999, 117:225-233.
30. Gandara D.R., Chansky K., Albain K.S., Gaspar L.E., Lara P.N., Kelly K., et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase-II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006, 8:116-121.
31. Christoph D.C., Kasper S., Gauler T.C., Loesch M., Engelhard D., Theegarten, et al. Beta-V-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small-cell lung cancer. Br J Cancer 2012, 107(5):823-830.
32. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
33. Berghmans T., Paesmans M., Sculier J.P. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 2011, 3((3) May):127-138.
34. Coate L.E., Massey C., Hope A., Sacher A., Barrett K., Pierre A., et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 2011, 6((3) March):537-544.
35. Firat S., Byhardt R.W., Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002, 54(2):357-364.
36. Luciani A., Bertuzzi C., Ascione G., Di Gennaro E., Bozzoni S., Zonato S., et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2009, 66((1) October):94-96.
37. Griggs J.J., Mangu P.B., Anderson H., Balaban E.P., Dignam J.J., Hryniuk W.M., American Society of Clinical Oncology, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012, 30(13):1553-1561.
38. Mazzoccoli G., Sothern R.B., Pazienza V., Piepoli A., Muscarella L.A., Giuliani F., Tarquini R. Circadian aspects of growth hormone-insulin-like growth factor axis function in patients with lung cancer. Clin Lung Cancer 2012, 13((1) January):68-74.
39. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012, 12(3):159-169.
40. Prado C.M., Lieffers J.R., McCargar L.J., Reiman T., Sawyer M.B., Martin L., Baracos V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008, 9((7) July):629-635.